YUPELRI (revefenacin) is a long-acting muscarinic antagonist (LAMA) indicated for the maintenance treatment of adults with moderate to very severe chronic obstructive pulmonary disease (COPD) [1]. It is administered once daily via inhalation [1].
How does YUPELRI work to treat COPD?
YUPELRI works by blocking the action of acetylcholine, a substance in the body that causes smooth muscles to contract. In the airways of people with COPD, this contraction can lead to bronchoconstriction, making it difficult to breathe. By blocking acetylcholine, YUPELRI relaxes these muscles, leading to bronchodilation and improved airflow [1].
When did YUPELRI become available?
YUPELRI was approved by the U.S. Food and Drug Administration (FDA) in October 2018 [1].
What is the difference between YUPELRI and other COPD inhalers?
YUPELRI is a LAMA, which is a class of medication used for long-term COPD management. Other common classes of COPD inhalers include short-acting beta-agonists (SABAs), long-acting beta-agonists (LABAs), and inhaled corticosteroids (ICS). While LAMAs primarily focus on bronchodilation, LABAs also provide bronchodilation with a longer duration of action than SABAs, and ICS are used to reduce airway inflammation, particularly in patients with frequent exacerbations or features of asthma. YUPELRI's specific mechanism as a LAMA differentiates its role in COPD therapy [1].
Are there any safety concerns or side effects associated with YUPELRI?
The most common side effects of YUPELRI include nasopharyngitis (common cold symptoms), oral candidiasis (thrush), urinary tract infection, and oropharyngeal pain [1]. It is important for patients to rinse their mouth after inhalation to help prevent oral thrush [1]. YUPELRI can also cause anticholinergic side effects such as blurred vision, constipation, and urinary retention [1]. It is contraindicated in patients with hypersensitivity to revefenacin or any of its ingredients [1].
Who makes YUPELRI?
YUPELRI is developed by Mylan (now Viatris) in collaboration with Theravance Biopharma [1].